Morgan Stanley’s Context Therapeutics CNTX Stock Holding History

Morgan Stanley’s Portfolio CNTX Stock Details CNTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$18.9K	Buy	34,121 +25,044	+276%	+$50.8K	﹤0.01%	6842
2026 Q1	$23.8K	Buy	+9,077	New	+$21.2K	﹤0.01%	6661
2025 Q3	–	Sell	-3,500	Closed	-$2.29K	–	8198
2025 Q2	$2.29K	Buy	3,500 +3,400	+3,400%	+$2.44K	﹤0.01%	7199
2025 Q1	$61	Sell	100 -127	-56%	-$111	﹤0.01%	7661
2024 Q4	$238	Buy	+227	New	+$393	﹤0.01%	7397
2022 Q4	–	Sell	-17,057	Closed	-$19K	–	7902
2022 Q3	$19K	Buy	17,057 +7,057	+71%	+$12.7K	﹤0.01%	6816
2022 Q2	$21K	Hold	10,000	–	–	﹤0.01%	6953
2022 Q1	$22K	Buy	10,000 +5,000	+100%	+$10.5K	﹤0.01%	7101
2021 Q4	$13K	Buy	+5,000	New	+$24.9K	﹤0.01%	7370

Other funds holding CNTX

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

OCA

Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return

BOCH

Blue Owl Capital Holdings New York $665M AUM 95.48% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

Morgan Stanley's CNTX Position: Q2 2026 in Review

Morgan Stanley increased its Context Therapeutics (CNTX) stake by 276% in Q2 2026, buying an estimated $50.8K and bringing the position to 34,121 shares worth $18.9K. The position accounts for ﹤0.01% of the portfolio, ranked #6842.

Morgan Stanley first reported a position in CNTX in Q4 2021 and has held it in 9 quarters since. The position peaked at $23.8K in Q1 2026. 79 funds tracked by Wall St. Rank hold CNTX as of Q2 2026.

Morgan Stanley held 34,121 shares of Context Therapeutics worth $18.9K as of Q2 2026.
Morgan Stanley bought 25,044 Context Therapeutics shares in Q2 2026, an estimated $50.8K.
Context Therapeutics made up ﹤0.01% of Morgan Stanley's portfolio in Q2 2026, its #6842 holding.
Morgan Stanley first reported a position in Context Therapeutics in Q4 2021 and has held it in 9 quarters since.
Morgan Stanley's Context Therapeutics position peaked at $23.8K in Q1 2026.
79 funds tracked by Wall St. Rank held Context Therapeutics as of Q2 2026.

Based on Morgan Stanley's 13F filing for Q2 2026, filed 13 Aug 2026.